Serum lipids and the progression of nephropathy in type 1 diabetes

被引:55
作者
Thomas, MC
Rosengård-Bärlund, M
Mills, V
Rönnback, M
Thomas, S
Forsblom, C
Cooper, ME
Taskinen, MR
Viberti, G
Groop, PH
机构
[1] Baker Heart Res Inst, Melbourne, Vic, Australia
[2] Univ Helsinki, Cent Hosp, Div Nephrol, Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Div Cardiol, Helsinki, Finland
[4] Univ London Kings Coll, Guys Hosp, Div Cardiovasc, London WC2R 2LS, England
关键词
D O I
10.2337/diacare.29.02.06.dc05-0809
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Dyslipidemia contributes to the progression of microvascular disease in diabetes. However, different lipid variables may be important at different stages of nephropathy. This study examines the pattern of dyslipidemia associated with the progression of nephropathy in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS - A total of 152 patients with type 1 diabetes were recruited in order to represent various phases of nephropathy. Patients were followed for 8-9 years, during which time they received standard care. Renal progression was defined a priori as a doubling in albumin excretion.(in patients with normo- or microalbuminuria) or a decline in creatinine clearance (in those with macroalbuminuria). A panel of lipid variables was determined and correlated with indexes of progression. RESULTS - in patients with normoalbuminuria (n = 66), progression was associated with male sex (P < 0.05), borderline albuminuria (P = 0.02), and LDL-free cholesterol (P = 0.02). In patients with microalbuminuria (it = 51), progression was independently associated with triglyceride content of VLDL and intermediate-density lipoprotein (both P < 0.05). In patients with macroalbuminuria (n = 36), a significant decline in the renal function (> 3 ml (.) min(-1.) year(-1)) was independently associated with poor glycemic control, hypertension, and LDL size (P < 0.05). When all patients with progressive nephropathy were analyzed together, only LDL cholesterol was predictive on multivariate analysis (P < 0.05), which masked the importance of triglyceride enrichment in microalbuminuria. CONCLUSIONS - Lipid variables are associated with progression of diabetic kidney disease, but the relationship is not the same at all stages. This finding has implications for the design of renoprotective strategies and the interpretation of clinical trials in type 1 diabetes.
引用
收藏
页码:317 / 322
页数:6
相关论文
共 27 条
[11]   High prevalence of small dense LDL in diabetic nephropathy is not directly associated with kidney damage: a possible role of postprandial lipemia [J].
Hirano, T ;
Oi, K ;
Sakai, S ;
Kashiwazaki, K ;
Adachi, M ;
Yoshino, G .
ATHEROSCLEROSIS, 1998, 141 (01) :77-85
[12]   PLASMA-LIPOPROTEINS AND RENAL-FUNCTION DURING SIMVASTATIN TREATMENT IN DIABETIC NEPHROPATHY [J].
HOMMEL, E ;
ANDERSEN, P ;
GALL, MA ;
NIELSEN, F ;
JENSEN, B ;
ROSSING, P ;
DYERBERG, J ;
PARVING, HH .
DIABETOLOGIA, 1992, 35 (05) :447-451
[13]   Progression of diabetic nephropathy [J].
Hovind, P ;
Rossing, P ;
Tarnow, L ;
Smidt, UM ;
Parving, HH .
KIDNEY INTERNATIONAL, 2001, 59 (02) :702-709
[14]   Transendothelial lipoprotein exchange and microalbuminuria [J].
Jensen, JS ;
Feldt-Rasmussen, B ;
Jensen, KS ;
Clausen, P ;
Henrik, SB ;
Nordestgaard, BG .
CARDIOVASCULAR RESEARCH, 2004, 63 (01) :149-154
[15]   Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria [J].
Jerums, G ;
Allen, TJ ;
Campbell, DJ ;
Cooper, ME ;
Gilbert, RE ;
Hammond, JJ ;
Raffaele, J ;
Tsalamandris, C .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (05) :890-899
[16]   PLASMA CHOLESTERYL ESTER TRANSFER PROTEIN AND ITS RELATIONSHIP TO PLASMA-LIPOPROTEINS AND APOLIPOPROTEIN A-I-CONTAINING LIPOPROTEINS IN IDDM PATIENTS WITH MICROALBUMINURIA AND CLINICAL NEPHROPATHY [J].
KAHRI, J ;
VIBERTI, GC ;
GROOP, PH ;
TASKINEN, MR ;
ELLIOTT, T .
DIABETES CARE, 1994, 17 (05) :412-419
[17]  
Kamanna VS, 2002, HISTOL HISTOPATHOL, V17, P497, DOI 10.14670/HH-17.497
[18]  
Kondo A, 2001, CLIN CHEM, V47, P893
[19]  
KROLEWSKI AS, 1994, KIDNEY INT, V45, pS125
[20]  
LAHDENPERA S, 1994, DIABETOLOGIA, V37, P681, DOI 10.1007/s001250050164